D.E. Shaw & Co
BCYC

D.E. Shaw & Co’s Bicycle Therapeutics BCYC Stock Holding History

D.E. Shaw & Co’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Buy
+25,457
New +$117K ﹤0.01% 4629
2026
Q1 		– Sell
-21,548
Closed -$153K – 4544
2025
Q4 		$153K Buy
+21,548
New +$159K ﹤0.01% 4366

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

D.E. Shaw & Co's BCYC Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Bicycle Therapeutics (BCYC) in Q2 2026: 25,457 shares worth $108K. The stake represents ﹤0.01% of the portfolio and ranks #4629 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in BCYC as recently as Q4 2025.

D.E. Shaw & Co first reported a position in BCYC in Q4 2025 and has held it in 2 quarters since. The position peaked at $153K in Q4 2025. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • D.E. Shaw & Co held 25,457 shares of Bicycle Therapeutics worth $108K as of Q2 2026.
  • Bicycle Therapeutics was a new D.E. Shaw & Co position in Q2 2026.
  • Bicycle Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4629 holding.
  • D.E. Shaw & Co first reported a position in Bicycle Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • D.E. Shaw & Co's Bicycle Therapeutics position peaked at $153K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.